Therapy Areas: Oncology
Seneca Therapeutics Launches Novel Cancer Gene Delivery Platform based on SVV-001 Technology
22 September 2021 - - US-based biopharmaceutical company Seneca Therapeutics, Inc has launched a novel Cancer Gene Delivery Platform based on SVV-001 technology, the company said.

STI refers to these new entities as SVV-001 Armed Gene Constructs. STI has a wealth of data, including from three clinical trials that SVV-001 is amongst the most cancer selective oncolytic viruses.

SVV-001 specificity to infect tumor cells is primarily due to the selective expression of eight genes that are characterized in the recently announced SVV-001 Patient Selection Test.

Chief among these genes is the receptor of SVV-001, namely Tumor Endothelial Marker 8.

TEM8 is selectively expressed on the surface of tumor cells in a variety of tumor types.

STI has now demonstrated that genes to enhance cancer therapy can easily be inserted into SVV-001.

The selectivity of expression of the genes inserted is equal to the selectivity of SVV-001 infection in tumor cells.

STI has confirmed SVV-001 can deliver genes up to ~27 Kda or ~700 base pairs into tumors sensitive to SVV-001.

Because SVV-001 is a natural, non-human virus, the manufacturing process to produce SVV-001 Armed Gene Constructs is much simpler, faster, and significantly less expensive than current virus or gene therapy vectors used in cancer gene delivery.

STI is in the process of producing and testing numerous SVV-001 Armed Gene Constructs carrying a variety of transgenes that are either immunostimulatory, aimed to reverse the immosuppressive environment in tumors, or express cancer neoantigens.

Of particular interest is the delivery of cancer neo-antigens whereby a patient's neo-antigens can be identified, synthesized and produced in just a few weeks.

SVV is currently testing an SVV-001 Armed Gene Construct expressing the model antigen ovalbumin to characterize the ability to deliver human neo-antigens.

The SVV-001 Patient Selection Test enables identification of patients who might benefit from SVV-001 therapy including SVV-001 Armed Gene Constructs.

The announcement regarding the SVV-001 Patient Selection Test was made last week.

The multiple dose IV infusion program for SVV-001 continues with data read out projected for early next year.

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 related products.

Seneca Therapeutics is also developing armed versions of SVV-001 that will selectively express gene product(s) that are inserted into the genome of SVV-001and create additional anti-tumor effects.


Related Headlines